J Med Genet

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 13 September 2006. doi:10.1136/jmg.2006.044859
Journal of Medical Genetics 2007;44:38-43
Copyright © 2007 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmg.2006.044859v1
44/1/38    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fanin, M
Right arrow Articles by Angelini, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fanin, M
Right arrow Articles by Angelini, C

ORIGINAL ARTICLE

Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations

M Fanin, A C Nascimbeni, C Angelini

Department of Neurosciences, University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy

Correspondence to:
Dr M Fanin
Venetian Institute of Molecular Medicine, via Giuseppe Orus 2, 35129 Padova, Italy; marina.fanin{at}unipd.it] Background: The diagnosis of calpainopathy is obtained by identifying calpain-3 protein deficiency or CAPN3 gene mutations. However, in many patients with limb girdle muscular dystrophy type 2A (LGMD2A), the calpain-3 protein quantity is normal because loss-of-function mutations cause its enzymatic inactivation. The identification of such patients is difficult unless a functional test suggests pursuing a search for mutations.

Materials and methods: A functional in vitro assay, which was able to test calpain-3 autolytic function, was used to screen a large series of muscle biopsy specimens from patients with unclassified LGMD/hyperCKaemia who have previously shown normal calpain-3 protein quantity.

Results: Of 148 muscle biopsy specimens tested,17 samples (11%) had lost normal autolytic function. CAPN3 gene mutations were identified in 15 of 17 patients (88%), who account for about 20% of the total patients with LGMD2A diagnosed in our series.

Conclusions: The loss of calpain-3 autolytic activity is highly predictive of primary calpainopathy, and the use of this test as part of calpainopathy diagnosis would improve the rate of disease detection markedly. This study provides the first evidence of the pathogenetic effect of specific CAPN3 gene mutations on the corresponding protein function in LGMD2A muscle and offers new insights into the structural–functional relationship of the gene and protein regions that are crucial for the autolytic activity of calpain-3.


Abbreviations: LGMD, limb girdle muscular dystrophy; LGMD2A, limb girdle muscular dystrophy type 2A; SSCP, single-strand conformational polymorphism; TTBS, Tris-buffered saline with Tween-20




This article has been cited by other articles:


Home page
BrainHome page
E. J. Groen, R. Charlton, R. Barresi, L. V. Anderson, M. Eagle, J. Hudson, M. S. Koref, V. Straub, and K. M. D. Bushby
Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A
Brain, December 1, 2007; 130(12): 3237 - 3249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd.